Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00422032 · ClinicalTrials.gov registry record · Phase 2
2 Arm Study of Clofarabine IV in MDS Patients
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT00422032: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00422032 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 60 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00422032, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to compare the effectiveness of 2 different doses of the drug clofarabine that can be given on a weekly schedule for the treatment of Myelodysplastic Syndrome (MDS). The safety of these two doses will also be compared. Primary Objective: Compare the response rates of two dose schedules of clofarabine in MDS. Secondary Objective: Compare response durations, survivals and side effects of the two schedules.
Interventions
- DRUG Clofarabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2006-01 |
| Est. Completion | 2011-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00422032
The ClinicalTrials.gov registry entry for NCT00422032 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Clofarabine is the first listed.
NCT00422032 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00422032 about?
NCT00422032 is a clinical study titled "2 Arm Study of Clofarabine IV in MDS Patients". The goal of this clinical research study is to compare the effectiveness of 2 different doses of the drug clofarabine that can be given on a weekly schedule for the treatment of Myelodysplastic Syndrome (MDS). The safety of these two doses will also be compared. Primary Objective: Compare the respo...
What is the current status of trial NCT00422032?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2006-01. Estimated completion is 2011-11.
What interventions are being tested in trial NCT00422032?
The interventions under investigation include: Clofarabine (DRUG).
Who is sponsoring clinical trial NCT00422032?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.